ATTD 2026 Clinical Data Recap: Exciting New Data with Omnipod 5

Reviewing key data presented at the 2026 Advanced Technologies & Treatments for Diabetes (ATTD), Within Range unpacks the latest real-world evidence & outcomes of various studies and analyses within the type 1 diabetes (T1D) population. Host Cindy Pickering, Clinical Services Manager at Insulet, is joined by Kellee Miller and Alex Nguyen, two senior leaders from Insulet's Medical Affairs team, to break down what the data means for healthcare providers (HCPs) and their patients. Kellee and Alex walk through a real-world analysis of over 176,000 Omnipod 5 users across the US, UK, Germany and France, revealing which optimised settings are most strongly associated with achieving greater than 70% time in range (TIR) - without increasing hypoglycaemia. Kellee and Alex also share results from the largest real-world analysis study of insulin pump persistence conducted in France and a recent health outcomes economics study explores how Omnipod 5 users are experiencing fewer hypoglycaemia-related emergency room visits compared with other Automated Insulin Delivery Systems (AIDs). --- How can continuous glucose monitoring and tubeless insulin delivery help people living with diabetes? Within Range is a podcast for healthcare professionals (HCPs), helping them stay up to date on the latest diabetes innovations. Within Range is presented by Kate Neal and Cindy Pickering (Clinical Services Managers at Insulet) who sit down with diabetes healthcare professionals from across the world to discuss clinical research, best practices and how Omnipod 5 Automated Insulin Delivery systems (AIDs) can help simplify diabetes management for patients with Type 1 diabetes (T1D). If you’re looking to improve your knowledge of AID and Omnipod 5, then this is the podcast for you. --- Disclaimer Note: The information in this podcast is accurate to the date of recording as of 30/03/2024.  Kelle Miller, Alex Nguyen and Cindy Pickering are employees of Insulet but their views and opinions expressed in this podcast are their own and do not necessarily reflect those of Insulet.  This Podcast is meant for healthcare professionals to better understand the Omnipod 5 System and its use within clinical practice settings.  The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with U-100 rapid acting insulin. Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide and www.omnipod.com/sscp for complete safety information including indications, contraindications. Omnipod 5 may not be available in your country.  INS-OHS-04-2026-00317 v1.0